Kronos Bio Inc
KRON
Get informed when a big investor buys or sells
+ FollowMarket Cap$53.65M
Close$
$1.69
92.4% upside
Current Fair Value
92.4% upsideUndervalued by 92.4% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $53.65 Million |
|---|---|
| Enterprise Value | $-12,265,104.00 |
| Dividend Yield | $- (-) |
| Earnings per Share | $-1.43 |
| Beta | 1.64 |
| Outstanding Shares | 60,807,000 |
Return
| Return on Equity | -80.80% |
|---|---|
| Return on Assets | -59.63% |
| Return on Invested Capital | -54.10% |
Valuation & Multiples
| P/E Ratio | -1.57 |
|---|---|
| PEG | 2.17 |
| Price to Sales | - |
| Price to Book Ratio | 0.88 |
| Enterprise Value to Revenue | -1.33 |
| Enterprise Value to EBIT | 0.23 |
| Enterprise Value to Net Income | 0 |
| Total Debt to Enterprise | -2.09 |
| Debt to Equity | 0.32 |
Revenue Sources
No data
Insider Trades
Institutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | -▼ 100.00% |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 0.00%▼ 31.46% |
|---|---|
| Total Invested | $1,579▼ 99.99% |
| Investors Holding | 1▼ 47.00% |
ESG Score
No data
About Kronos Bio Inc
63 employeesKronos Bio is a clinical-stage biopharmaceutical company dedicated to discovering and developing therapies that seek to transform the lives of those affected by cancer. The company focuses on targeting dysregulated transcription factors ...